Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Tracon Pharma (TCON), 24% surge in interest
• Exelixis (EXEL), 19% surge in interest

Pipeline and key clinical candidates for these companies:

Tracon is a clinical-stage biopharmaceutical company that says utilizing “a cost-efficient, CRO-independent, product development platform” it is advancing its pipeline of novel targeted cancer therapeutics and partnering with other life science companies. The company’s clinical-stage pipeline includes Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; and TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer.

Exelixis is an oncology company that says it is “innovating next-generation medicines and regimens at the forefront of cancer care.” The company says it is rapidly evolving its product portfolio to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics.

Recent news on these stocks:

February 27

In a regulatory filing, Exelixis executive VP Patrick Haley disclosed the sale of 47,020 common shares of the company on February 23 at a price of $21.45 per share.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.